Mammalian Target of Rapamycin (mTOR) Inhibitors as Anti-Cancer Agents

Publisher： Bentham Science Publishers

E-ISSN： 1873-5576|4|8|621-635

ISSN： 1568-0096

Source： Current Cancer Drug Targets, Vol.4, Iss.8, 2004-12, pp. : 621-635

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Anticancer Mammalian Target of Rapamycin (mTOR) Signaling Pathway Inhibitors: Current Status, Challenges and Future Prospects in Management of Epilepsy

By  

CNS & Neurological Disorders - Drug Targets (Formerly Current Drug Targets - CNS & Neurological Disorders), Vol. 15, Iss. 8, 2016-09 ,pp. : 945-955

Bentham Science Publishers

Access to resources Recommend Favorite

Mammalian Target of Rapamycin (mTOR) Inhibitors: Potential Uses and a Review of Haematological Adverse Effects

By Sofroniadou Sofia   Goldsmith David  

Drug Safety, Vol. 34, Iss. 2, 2011-02 ,pp. : 97-115

Adis International

Access to resources Recommend Favorite

mTOR Pathway and mTOR Inhibitors as Agents for Cancer Therapy

By  

Current Cancer Drug Targets, Vol. 8, Iss. 8, 2008-12 ,pp. : 647-665

Bentham Science Publishers

Access to resources Recommend Favorite

mTOR pathway inhibitors in cancer therapy: moving past rapamycin

By Wacheck Volker  

Pharmacogenomics, Vol. 11, Iss. 9, 2010-09 ,pp. : 1189-1191

Future Medicine

Access to resources Recommend Favorite

Inhibitors of the mammalian target of rapamycin

By Dancey Janet E  

Expert Opinion on Investigational Drugs, Vol. 14, Iss. 3, 2005-03 ,pp. : 313-328

Informa Healthcare

Access to resources Recommend Favorite